A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)Kalyan Nadiminti, Yogesh Jethava, Allyson Schultz et al.|Blood|2018Cited by 5
A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)Christopher Strouse, Yogesh Jethava, Kalyan Nadiminti et al.|Transplantation and Cellular Therapy|2019Cited by 1